Last reviewed · How we verify
Cynara Scolymus
Cynara Scolymus is a Nitrate Vasodilator [EPC] Small molecule drug developed by Stefan Fischli. It is currently FDA-approved for Relief of occasional eye overexertion.
At a glance
| Generic name | Cynara Scolymus |
|---|---|
| Sponsor | Stefan Fischli |
| Drug class | Nitrate Vasodilator [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Relief of occasional eye overexertion
Common side effects
Key clinical trials
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Multidomain Interventions for Elderly Individuals in Residential Structures (NA)
- Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial (PHASE2)
- Food Supplementation With Eufortyn Colesterolo Plus for LDL Modulation in Subjects With Polygenic Hypercholesterolemia (NA)
- Artichoke and Bergamot Phytosome (NA)
- The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects With Newly Detected Impaired Fasting Glycaemia. (NA)
- Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption (NA)
- Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cynara Scolymus CI brief — competitive landscape report
- Cynara Scolymus updates RSS · CI watch RSS
- Stefan Fischli portfolio CI
Frequently asked questions about Cynara Scolymus
What is Cynara Scolymus?
Cynara Scolymus is a Nitrate Vasodilator [EPC] drug developed by Stefan Fischli, indicated for Relief of occasional eye overexertion.
What is Cynara Scolymus used for?
Cynara Scolymus is indicated for Relief of occasional eye overexertion.
Who makes Cynara Scolymus?
Cynara Scolymus is developed and marketed by Stefan Fischli (see full Stefan Fischli pipeline at /company/stefan-fischli).
What drug class is Cynara Scolymus in?
Cynara Scolymus belongs to the Nitrate Vasodilator [EPC] class. See all Nitrate Vasodilator [EPC] drugs at /class/nitrate-vasodilator-epc.
What development phase is Cynara Scolymus in?
Cynara Scolymus is FDA-approved (marketed).
Related
- Drug class: All Nitrate Vasodilator [EPC] drugs
- Manufacturer: Stefan Fischli — full pipeline
- Indication: Drugs for Relief of occasional eye overexertion
- Compare: Cynara Scolymus vs similar drugs
- Pricing: Cynara Scolymus cost, discount & access